Key Details
Price
$4.90Last Dividend
$0.09Annual ROE
6.86%Beta
0.86Events Calendar
Next earnings date:
Jan 31, 2025Recent quarterly earnings:
Nov 14, 2024Recent annual earnings:
May 15, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
Sept 30, 2024Next split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
Mizuho Financial Group, Inc. (NYSE:MFG) will hold its Q2 2024 earnings conference call on November 16, 2024, at 1:30 AM ET. The call will feature company representatives, including Orita Natsuki, the Chief Investor Relationship Officer, and Masahiro Kihara, the President and Group CEO. Takahiro Yano from J.P. Morgan Securities Japan Co., Ltd. will also participate in the call.
The global attention has mainly been on the choices of the United States Federal Reserve (the Fed), especially about interest rates and the economy's condition. Since inflation has been controlled well, the Fed has chosen to lower interest rates at the fastest rate in 16 years.
With US inflation appearing to decrease, many on Wall Street are optimistic about a "soft landing" for the economy. However, Mizuho, Japan's third-largest bank, cautions that if this expectation is incorrect, it may result in short-term fluctuations in the market.
Mizuho (MFG) could see an increase in its stock price due to rising confidence in its earnings potential, as indicated by its upgrade to a Zacks Rank #2 (Buy).
On August 28, 2024, Mizuho Americas announced that Thierry Perrein has been appointed as Managing Director and Credit Strategist. He will mainly focus on REITs and Non-bank Financials, enhancing Mizuho's services in these areas. Thierry will report to Brian Connors, who is the Managing Director and Head of Investment Grade Trading in Mizuho Americas' Fixed Income Division.
WUXI and SUZHOU, China, Aug. 1, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a top global Contract Research, Development and Manufacturing Organization (CRDMO), has announced that four of its manufacturing sites and the Suzhou Biosafety Testing Center in China have received Good Manufacturing Practice (GMP) certificates from the European Medicines Agency (EMA). This achievement highlights the company's dedication to maintaining high international quality standards across its operations. After thorough inspections of its facilities in Wuxi, the EMA granted GMP certificates for the production and services related to eight biologics, confirming WuXi Bio's ability to serve clients worldwide.
Investors interested in stocks from the Banks - Foreign sector have probably already heard of Mizuho (MFG) and ICICI Bank Limited (IBN). But which of these two stocks is more attractive to value investors?
NEW YORK, June 26, 2024 (GLOBE NEWSWIRE) -- Mizuho Financial Group, Inc. hereby announces that it filed an annual report on Form 20-F with the U.S. Securities and Exchange Commission on June 26, 2024.
NEW YORK, June 11, 2024 (GLOBE NEWSWIRE) -- Mizuho Americas today announced the hiring of Steven Valiquette as Managing Director and Senior Equity Research Analyst, covering Health Care Technology & Distribution. Based in New York, Valiquette reports to the Head of Americas Equity Research, Bill Featherston.
Investors interested in stocks in the Banks - Foreign sector may want to consider either Mizuho (MFG) or National Australia Bank Ltd. (NABZY). However, which of these two stocks is more appealing to value investors?
FAQ
- What is the primary business of Mizuho Financial?
- What is the ticker symbol for Mizuho Financial?
- Does Mizuho Financial pay dividends?
- What sector is Mizuho Financial in?
- What industry is Mizuho Financial in?
- What country is Mizuho Financial based in?
- When did Mizuho Financial go public?
- Is Mizuho Financial in the S&P 500?
- Is Mizuho Financial in the NASDAQ 100?
- Is Mizuho Financial in the Dow Jones?
- When was Mizuho Financial's last earnings report?
- When does Mizuho Financial report earnings?